Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-04-15 9:59:54 PM | Chg. -6.37 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 898.33USD | -0.70% | 21,973 Turnover: 19.86 mill. |
-Bid Size: - | -Ask Size: - | 98.63 bill.USD | - | 24.25 |
Assets
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 2,575.8000 | 2,890.4000 | 3,221.6000 | 3,482.2000 | 3,763 | ||||||
| Intangible Assets | - | - | - | - | 915.5000 | ||||||
| Long-Term Investments | 1,755 | 3,256.8000 | 3,135.6000 | 6,838 | 6,591.8000 | ||||||
| Fixed Assets | 5,286.9000 | 7,116.1000 | 7,384.2000 | 11,419.9000 | 13,330.4000 | ||||||
| Inventories | 1,151.2000 | 1,415.5000 | 1,916.6000 | 1,951.3000 | 2,401.9000 | ||||||
| Accounts Receivable | 1,723.7000 | 2,100 | 3,111.5000 | 6,036.5000 | 5,328.7000 | ||||||
| Cash and Cash Equivalents | 1,467.7000 | 1,617.8000 | 2,193.7000 | 2,885.6000 | 3,105.9000 | ||||||
| Current Assets | 6,447.6000 | 7,689.1000 | 9,779.1000 | 14,014.9000 | 15,884.1000 | ||||||
| Total Assets | 11,734.5000 | 14,805.2000 | 17,163.3000 | 25,434.8000 | 29,214.5000 | ||||||
Liabilities
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 218.2000 | 418.1000 | 475.5000 | 564 | 589.2000 | ||||||
| Long-term debt | 708.5000 | 713.9000 | 2,695.7000 | 1,980 | 2,701.4000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 2,977.2000 | 3,715.5000 | 6,138 | 6,666 | 6,550.5000 | ||||||
| Share Capital | .1000 | .1000 | .1000 | .1000 | .1000 | ||||||
| Total Equity | 8,757.3000 | 11,089.7000 | 11,025.3000 | 18,768.8000 | 22,664 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 11,734.5000 | 14,805.2000 | 17,163.3000 | 25,434.8000 | 29,214.5000 | ||||||
Income Statement
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 6,710.8000 | 7,863.4000 | 8,497.1000 | 16,071.7000 | 12,172.9000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 2,534.4000 | 2,209.8000 | 3,576.6000 | 8,946.8000 | 4,738.9000 | ||||||
| Interest Income | -28.2000 | -30.2000 | -56.9000 | -57.3000 | -59.4000 | ||||||
| Income Before Taxes | 2,553.5000 | 2,429.1000 | 3,810.4000 | 9,325.8000 | 4,858.8000 | ||||||
| Income Taxes | -109.1000 | -313.3000 | 297.2000 | 1,250.5000 | 520.4000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 2,444.4000 | 2,115.8000 | 3,513.2000 | 8,075.3000 | 4,338.4000 | ||||||
Per Share
Cash Flow
| 2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 2,195.1000 | 2,430 | 2,618.1000 | 7,081.3000 | 5,014.9000 | ||||||
| Cash Flow from Investing Activities | -1,463 | -2,027.8000 | -70.6000 | -5,384.7000 | -3,784.6000 | ||||||
| Cash Flow from Financing | -77.1000 | -252.1000 | -1,970.5000 | -1,005.8000 | -1,009 | ||||||
| Decrease / Increase in Cash | 655 | 150.1000 | 577 | 690.8000 | 221.3000 | ||||||
| Employees | 7,400 | 8,100 | 9,123 | 10,368 | - | ||||||
